Please assess the completion status of the following clinical trial:

Trial Title: Study Evaluating Prophylaxis Treatment & Characterizing Efficacy, Safety, & PK Of B-Domain Deleted Recombinant FVIII

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male subjects, aged less than 6 years, with moderately severe to severe hemophilia A.~* A negative FVIII inhibitor titer at screening, and a medical history negative for a past FVIII inhibitor.~* At least 20 exposure days to any FVIII replacement product.~* Adequate hepatic and renal function~* CD4 count \> 400 cells/uL, and if receiving antiviral therapy must be on a stable regimen~Additional criteria for subjects participating in the PK assessment:~* Male subjects as described immediately above except they must have a FVIII Activity of less than or equal to 1% confirmed by the central laboratory screening test~* Age \< 6 years at time of PK assessment.~* The subject's size is sufficient to permit PK-related phlebotomy.~* The subject is able to comply with the procedures conducted during the PK assessment, including a mandatory 72-hour washout period preceding the PK assessment.~Exclusion Criteria:~* A history of FVIII inhibitor.~* Presence of a bleeding disorder in addition to hemophilia A.~* Treatment with any investigational drug or device within 30 days before the time of signing the informed consent form.~* Major or orthopedic surgery planned to occur during the course of the study.~* Regular (e.g., daily, every other day) use of antifibrinolytic agents or medications known to influence platelet function such as aspirin or certain nonsteroidal anti-inflammatory drugs (NSAIDs), or regular, concomitant therapy with immunomodulating drugs (e.g., intravenous immunoglobulin \[IVIG\], routine systemic corticosteroids).~* Known hypersensitivity to hamster protein.

- Gender: MALE
- Minimum Age: 6 Months
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): On-Demand therapy for 6 months, followed by Routine Prophylaxis treatment for 1 year.
- 2 (Type: EXPERIMENTAL): Routine Prophylaxis Crossover

Based on this trial design, predict the completion outcome and termination type (if applicable).